The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.